An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Following successful smoking cessation, smokers with schizophrenia are vulnerable to relapse shortly after treatment discontinuation. Our objective was to assess the feasibility and effectiveness of a 12-month relapse prevention intervention in recently abstinent smokers with schizophrenia. METHOD: Adult outpatient smokers with schizophrenia received weekly cognitive behavioral therapy groups, bupropion slow release, transdermal nicotine patch, and nicotine gum or lozenge for three months. Subjects with seven-day point prevalence abstinence at month 3 received an additional 12 months (months 4-15) of therapy with bupropion, transdermal nicotine patch, and nicotine gum/lozenge in conjunction with relapse prevention-based cognitive behavioral therapy groups that were held weekly in month 4, biweekly in months 5-6, and monthly in months 7-15. RESULTS: Seventeen of 41 participants (41.5%) attained biochemically verified self-report of seven-day point prevalence abstinence at the end of three months of treatment and entered relapse prevention treatment. There was an 81% attendance rate at relapse prevention groups. At the end of the 12-month relapse prevention phase (month 15 overall), 11 of 17 (64.7%) demonstrated biochemically verified seven-day point prevalence abstinence, and 10 of 17 (58.8%) reported four-week continuous abstinence. Almost one quarter of the sample (23.5%) demonstrated long-term prolonged abstinence through the end of the trial. There were no clinically detected cases of psychiatric symptom exacerbation. One participant, who was managed as an outpatient, self-reported psychiatric symptom exacerbation in the interim period between study visits. CONCLUSIONS: Extended duration smoking cessation treatment is well-tolerated and may improve smoking outcomes for recently abstinent smokers with schizophrenia. Controlled trials are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fagerström, K.-O. (1978) · Addictive Behaviors · doi:10.1016/0306-4603(78)90024-2 · Cited by 2,221 · cited 2×
“Baseline assessments included a smoking behavior questionnaire on which participants reported prior cessation attempts in which they attained at least 24 hours abstinence, the Fagerström Test for Nicotine Dependence (Fagerström, 1978), a self-report questionnaire with total scores ranging from 0 to 10, with higher s…”
MethodCauses of the excess mortality of schizophrenia
Brown, S., Inskip, H., & Barraclough, B. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.3.212 · Cited by 1,087
Prevalence of smoking among psychiatric outpatients
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.8.993 · Cited by 1,058 · cited 2×
“It has long been recognized that rates of smoking and smoking-related morbidity and mortality are dramatically higher among individuals with schizophrenia compared with those in the general population (de Leon et al., 1995; Fiore, Bailey, & Cohen, 1996; Hughes, 1986; Olincy, Young, & Freedman, 1997; Strasser et al., 2…”
BackgroundHays, J. T., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzales, D., Durcan, M. J., Sachs, D. P. L., Wolter, T. D., Buist, A. S., Johnston, J. A., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00011 · Cited by 343
Mental disorders and cause-specific mortality
Joukamaa, M., HeliöVaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.6.498 · Cited by 328 · cited 2×
“org eases such as pulmonary and cardiovascular disease are two to six times higher among individuals with schizophrenia than among age-matched controls (Brown, Inskip, & Barraclough, 2000; Curkendall, Mo, Glasser, Rose Stang, & Jones, 2004; Enger, Weatherby, Reynolds, Glasser, & Walker, 2004; Goff et al., 2005; Joukam…”
BackgroundInterventions for smoking cessation and reduction in individuals with schizophrenia
Tsoi, D. T., Porwal, M., & Webster, A. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007253.pub3 · Cited by 304
Baker, A., Richmond, R., Haile, M., Lewin, T. J., Carr, V. J., Taylor, R. L., Jansons, S., & Wilhelm, K. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1934 · Cited by 255
Evins, A. E., Cather, C., Culhane, M. A., Birnbaum, A., Horowitz, J., Hsieh, E., Freudenreich, O., Henderson, D. C., Schoenfeld, D. A., Rigotti, N. A., et al. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0b013e3180ca86fa · Cited by 179 · cited 8×
“…abstinent with cognitive-behavioral therapy, bupropion, and nicotine replacement therapy remaining abstinent from smoking 6 months following treatment discontinuation in one study (George et al., 2008) and 28% remaining abstinent 12 months after nicotine taper in another (Evins et al., 2007).”
BackgroundMethodResultInfluentialSelf-citationExtended nortriptyline and psychological treatment for cigarette smoking
Hall, S. M., Humfleet, G. L., Reus, V. I., Muñoz, R. F., & Cullen, J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.2100 · Cited by 158 · cited 2×
“, 2001), but extended-duration pharmacotherapy does not improve abstinence rates at end of extended treatment among those who do not achieve initial abstinence at the end of a standard 12-week treatment period (Hall et al., 2004).”
BackgroundAgboola, S., McNeill, A., Coleman, T., & Leonardi Bee, J. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.02996.x · Cited by 150
Cited by
Relapse prevention interventions for smoking cessation
Hajek, P., Stead, L. F., West, R., Jarvis, M., Hartmann-Boyce, J., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003999.pub4 · Cited by 467
Evins, A. E., Cather, C., Pratt, S. A., Pachas, G. N., Hoeppner, S. S., Goff, D. C., Achtyes, E. D., Ayer, D., & Schoenfeld, D. A. (2014) · JAMA · doi:10.1001/jama.2013.285113 · Cited by 207
Self-citationSmoking cessation and reduction in people with chronic mental illness
Tidey, J. W., & Miller, M. E. (2015) · BMJ · doi:10.1136/bmj.h4065 · Cited by 166
Relapse prevention interventions for smoking cessation
Livingstone-Banks, J., Norris, E., Hartmann-Boyce, J., West, R., Jarvis, M., & Hajek, P. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003999.pub5 · Cited by 94
Relapse prevention interventions for smoking cessation
Livingstone-Banks, J., Norris, E., Hartmann-Boyce, J., West, R., Jarvis, M., Chubb, E., & Hajek, P. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003999.pub6 · Cited by 77
Metadata
- Authors
- Cather, C., Dyer, M. A., Burrell, H. A., Hoeppner, B., Goff, D. C., & Evins, A. E.
- Venue
- Journal of Dual Diagnosis
- Publisher
- Informa UK Limited
- Published
- 2013-02
- Volume
- 9
- Issue
- 1
- Pages
- 87-93
- ISSN
- 1550-4263 (ISSN-L)
- 1550-4271
- OpenAlex
- W1971489773
- Cited by
- 30
- References
- 11
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia. https://app.cochat.ai/papers/10.1080/15504263.2012.749559
- The paper
- Cather, C., Dyer, M. A., Burrell, H. A., Hoeppner, B., Goff, D. C., & Evins, A. E. (2013). An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia. Journal of Dual Diagnosis. https://doi.org/10.1080/15504263.2012.749559
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.